Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. - Wikidata - awgldk - TriplyDB

Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.

Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.

http://www.wikidata.org/entity/Q37602233

about

Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications Foetal Cell Transplantation for Parkinson's Disease: Focus on Graft-Induced Dyskinesia Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.Neuronal circuits and physiological roles of the basal ganglia in terms of transmitters, receptors and related disorders What Mechanisms Are Responsible for the Reuptake of Levodopa-Derived Dopamine in Parkinsonian Striatum?Neuroimaging of Parkinson's disease: Expanding views.On the Complexity of Brain Disorders: A Symptom-Based Approach.Neuroimaging in Parkinson disease: from research setting to clinical practice.Recent imaging advances in neurology.Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers.Therapeutic efficacy of AAV8-mediated intrastriatal delivery of human cerebral dopamine neurotrophic factor in 6-OHDA-induced parkinsonian rat models with different disease progression.New treatments for the motor symptoms of Parkinson's disease.Distinctive in vitro signal transduction profile of NLX-112, a potent and efficacious serotonin 5-HT1A receptor agonist.Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.Functional correlates of exaggerated oscillatory activity in basal ganglia output in hemiparkinsonian rats.A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier.Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.Serotonin System Implication in l-DOPA-Induced Dyskinesia: From Animal Models to Clinical Investigations.Emerging drugs for levodopa-induced dyskinesia.Central pharmacokinetics of levodopa: Lessons from imaging studies.Molecular imaging of levodopa-induced dyskinesias.Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.Chemical anatomy of pallidal afferents in primates.Nondopaminergic treatments for Parkinson's disease: current and future prospects.l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?Neuroimaging in Parkinson's disease: a future perspective.Serotonin transporter in Parkinson's disease: A meta-analysis of positron emission tomography studies.Early Degeneration of Both Dopaminergic and Serotonergic Axons - A Common Mechanism in Parkinson's Disease.Dopamine and serotonin modulation of motor and non-motor functions of the non-human primate striato-pallidal circuits in normal and pathological states.Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias.Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs.Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease.Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate.Chronic exposure to dopamine agonists affects the integrity of striatal D2 receptors in Parkinson's patients.Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.Serotonin hyperinnervation of the striatum with high synaptic incidence in parkinsonian monkeys.Cell Therapy for Parkinson's Disease.

P2860

Q21129423-9079245A-07F1-4EB4-9F75-EA87741EFE3F Q26765499-EE454ED2-5599-4FCF-9B15-362DB5267CA7 Q26768220-DEB76C04-CCF2-499F-B0FB-0F4A6DE50B15 Q27303857-8AB7667D-C1D8-4107-BCDD-46E7C153C13F Q28069529-052B5C74-40C0-41B7-97FB-DBA4FFD1BC37 Q28078271-0F59048A-AAAA-4D88-BCD0-7E95311C6AFB Q28387732-7BFF1831-71D6-470F-8DBE-BAF18C255300 Q30389213-FE41A6DA-E511-4C28-A78E-898745464445 Q30868628-60FBC126-4C2D-4EA0-9868-E3F126BD90CF Q30916063-48459B9C-9EBB-464F-B9E5-F676AC497583 Q31158920-11585049-D72B-4AB3-B97C-4B66CE11DEFB Q33807060-F57156E8-A94A-4267-BD0B-76E7133A706D Q34443682-9A81F8EC-643E-460A-82FA-F4A0CFF31796 Q34557860-FBC95C56-B120-4C21-8FC5-6B344180C5CF Q34795714-B1D418B8-B5CC-411A-AD71-765CB4CEE8AF Q35053960-113695BE-1058-41F8-B914-5FF8CFAD2397 Q36972794-EA2CAECC-AB83-4FCC-A995-9AC390067DA0 Q37277039-DE342E67-CCA5-4771-8726-8B56B769E56B Q37512670-0AA8AAE1-31E2-4DCE-9238-99503CAE03F9 Q38218100-553EF9DE-C4DD-4E44-8833-1BA5C6FD688C Q38242091-CE2CC261-3177-4459-AA92-FB1BBF512BAE Q38255967-5AB2A2CA-2860-49D2-9574-0F19BB9BF3E0 Q38355582-903045D4-E09C-46C1-A022-7D1B5114E201 Q38658203-4747468A-2EC0-4C25-8768-501C4501640B Q38793660-77B99499-4014-4E9D-9AD4-C83ACB6F5E62 Q38845546-4A8231D4-3CD8-47F7-A96A-04928CEACAB2 Q38951947-3DAB9E6A-09BA-464D-A4DC-5B8B95029514 Q39015987-C5654F29-3E98-4E1C-8A6C-9482C5B45A4B Q39055550-CEAA8EA7-AF55-408C-8B87-AF9FBD96DBD6 Q39075710-6A017D67-D950-4A86-B8F0-7FF4728A4109 Q39125374-192592ED-BDC9-4E85-977B-4EC2B0E2A94B Q39324877-541184C5-0945-4DCB-A204-40064CA27AA7 Q40379397-7EACC542-4DCD-4276-B3FA-CC73D90C5E45 Q40696539-D02FB810-6EF9-4384-8089-4D915A034830 Q40790760-93541F5A-46CB-490B-82C2-6F93A53814FA Q41566638-49230B91-6CCC-41BB-B35A-DE09814A27E5 Q41684008-1C9D0102-01B6-4C41-988D-F42DC044B974 Q42369736-526AD772-3895-435A-B15F-B2D33A73E973 Q42483704-62DAA1AA-D0D7-4F34-A2A5-714CB14FEAD2 Q45740164-0DBDF194-3921-420E-B708-10DA10FB1029

P2860

Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.

http://www.wikidata.org/entity/Q37602233

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 February 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Serotonergic mechanisms respon ...... Parkinson's disease patients.

@en

Serotonergic mechanisms respon ...... Parkinson's disease patients.

@nl

type

label

Serotonergic mechanisms respon ...... Parkinson's disease patients.

@en

Serotonergic mechanisms respon ...... Parkinson's disease patients.

@nl

prefLabel

Serotonergic mechanisms respon ...... Parkinson's disease patients.

@en

Serotonergic mechanisms respon ...... Parkinson's disease patients.

@nl

P1433

Q37602233-DF9AF0FF-325F-43E5-B44D-606F5AA6C0D3

P1476

Q37602233-A89BF599-9D19-4325-B161-ECC88AFC3187

P2093

Q37602233-0FC72A6F-3C27-49B6-8678-B8633566885E

Q37602233-1BD557D4-D60A-45CE-A08F-BADF1129E6CF

Q37602233-3D25AE86-4C0E-40B9-BD1D-3C5EADEE8D2E

Q37602233-4833DA02-4C8C-4079-AED0-081DFAD8FD9A

Q37602233-AC7092C3-B750-4F78-A4B6-66391D0EC1FE

Q37602233-B58BF8A9-ADD7-444C-AE93-F7A0E15CD956

Q37602233-B826390A-426C-440E-A5AD-FDF186B7CC48

P2860

Q37602233-045C31E9-49DA-4C82-A94A-8747BE5F9D18

Q37602233-100EACEC-5874-4CE2-8836-564BEB243E2F

Q37602233-11599B27-0D4A-4B75-9966-8A7532D5FCB6

Q37602233-11B4EE9C-33AD-4D7F-8A1B-2526926975FE

Q37602233-1E2A379E-BFC1-42FC-BCDD-5032FA107838

Q37602233-2190FD5E-9372-468A-9600-CE3718FD861A

Q37602233-2FC7877F-7634-4729-BE75-A4281E1742B5

Q37602233-31C6052B-CD48-4BAC-9EE6-757C87513F6F

Q37602233-335FC1F1-1030-41A3-85D2-2608EBBE2B8D

Q37602233-3A6158E1-0DD5-47DD-A502-117A94980062

P304

Q37602233-6B5D30D0-05B3-4BCE-8951-8D1C4A60D2F2

P31

Q37602233-FC18FE70-CF3A-4B24-8A41-63550787DAA5

P356

Q37602233-8352F469-F21A-4203-AF47-D7CC29F2554E

P407

Q37602233-5E92C8F5-A2CA-47CC-9568-E8C98307CF39

P433

Q37602233-29C1FC64-399B-42E2-8C09-235765DBF00D

P478

Q37602233-E6B917EA-B466-4AEB-9EE6-9E1F72C4679F

P50

Q37602233-4A98B69E-6A4F-4320-99C7-98E43B1A7BDC

Q37602233-AC5BC75F-8A20-42CB-B07B-9FEDD43E0F6B

P577

Q37602233-42D5E4B7-3D1D-45F7-9BA5-884D7AD38AE3

P698

Q37602233-5D27DBB1-9D73-435B-BE6D-567EA2928DA9

P921

Q37602233-784E9C27-503B-4E1A-B3CA-B4F9044ABB63

Q37602233-AED4F2E1-6C72-4D63-A1E8-29FDC16D0300

Q37602233-DEB896F6-83F9-432F-9F2A-68727F4239DC

Q37602233-E57EBD42-BBFB-4E2F-ADF9-AA0B34A98A16

P932

Q37602233-E46B011C-38B3-4F2D-9C10-1E669AE1070B

P356

P1433

Journal of Clinical Investigation

P1476

Serotonergic mechanisms respon ...... Parkinson's disease patients.

@en

P2093

Clare Loane

http://www.w3.org/2001/XMLSchema#string

Kit Wu

http://www.w3.org/2001/XMLSchema#string

Lorenzo Kiferle

http://www.w3.org/2001/XMLSchema#string

Marios Politis

http://www.w3.org/2001/XMLSchema#string

Paola Piccini

http://www.w3.org/2001/XMLSchema#string

Peter Bain

http://www.w3.org/2001/XMLSchema#string

Sophie Molloy

http://www.w3.org/2001/XMLSchema#string

P2860

"Off period" dystonia and "on period" choreoathetosis in levodopa-treated patients with Parkinson's disease

Estimation of the number of "true" null hypotheses in multivariate analysis of neuroimaging data.

Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?

Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models.

Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study.

Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.

Concentrations and effects of buspirone are considerably reduced by rifampicin

Distribution volume ratios without blood sampling from graphical analysis of PET data.

Buspirone in the treatment of levodopa induced dyskinesias.

Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.

P304

1340-1349

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI71640

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

David J. Brooks

Federico Turkheimer

P577

2014-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24531549

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3934188

http://www.w3.org/2001/XMLSchema#string